Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07689175 · ClinicalTrials.gov registry record · Phase 2
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07689175 is a Phase 2 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT07689175, a Phase 2 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab (3 mg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-10-31 |
| Est. Completion | 2032-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07689175
The ClinicalTrials.gov registry entry for NCT07689175 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT07689175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07689175 about?
NCT07689175 is a clinical study titled "Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma". The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.
What is the current status of trial NCT07689175?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-10-31. Estimated completion is 2032-10-31.
What interventions are being tested in trial NCT07689175?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (3 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT07689175?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.